AstraZeneca data at WCLC advance ambition to have an AstraZeneca medicine for more than half of all patients treated for lung cancer by 2030
New data across diverse innovative therapeutic options showcase commitment to redefining lung cancer outcomes. AstraZeneca advances its lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), Read More …